Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study

Leukemia

Volumn 24, Issue 5, 2010, Pages 909-913

  Ho, P A ^a,b   Alonzo, T A ^c   Kopecky, K J ^d   Miller, K L ^a   Kuhn, J ^a   Zeng, R ^a   Gerbing, R B ^e   Raimondi, S C ^f   Hirsch, B A ^g   Oehler, V ^a,b   Hurwitz, C A ^h   Franklin, J L ^c,i   Gamis, A S ^j   Petersdorf, S H ^b   Anderson, J E ^k   Reaman, G H ^l   Baker, L H ^m   Willman, C L ⁿ   Bernstein, I D ^a,b   Radich, J P ^a,b   Appelbaum, F R ^a,b   Stirewalt, D L ^a,b   Meshinchi, S ^a,b   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h Reata Pharma   (United States)

ⁱ AMGEN INC   (United States)

^j CHILDREN S MERCY HOSPITAL   (United States)

^k Katmai Oncology Group   (United States)

^l GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^m UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF NEW MEXICO   (United States)

more..

Author keywords

Acute myeloid leukemia; FLT3; IDH1; Isocitrate dehydrogenase; NPM; Pediatric AML

Indexed keywords

CD135 ANTIGEN; DNA; ISOCITRATE DEHYDROGENASE 1; OXIDOREDUCTASE; PROTEIN IDH1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BONE MARROW; CHILD; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GERM LINE; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMOGENESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 77952424259     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.56     Document Type: Article

References (18)

1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multi-forme. Science 2008; 321: 1807-1812.
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
3. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7-11.
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
5. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-474.
6. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009; 125: 353-355.
7. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
8. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxan-trone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100: 3869-3876.
9. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113: 6558-6566.
10. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323-3329.
11. Petersdorf SH, Rankin C, Head DR, Terebelo HR, Willman CL, Balcerzak SP et al. Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). Am J Hemato 2007; 82: 1056-1062.
12. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
13. Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006; 107: 3724-3726.
14. Hayden JT, Fruhwald MC, Hasselblatt M, Ellison DW, Bailey S, Clifford SC. Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 2009; 8: 1806-1807.
15. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
16. Walmsley SR, Chilvers ER, Whyte MK. Hypoxia, hypoxia inducible factor and myeloid cell function. Arthritis Res Ther 2009; 11: 219-226.
17. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009; 102: 19-65.
18. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009; 13: 2780-2786.